Pilot participants have access to a version of Clear Labs' sequencing and analysis platform that is designed for high-volume food safety and quality testing.
CytoReason's machine-learning algorithms extract information from multi-omic measurements to improve indication prioritization and highlight new treatment targets.
With its technology, the company hopes to connect more cancer patients being treated in community-based practices to beneficial clinical trials based on genomic biomarkers.
The researchers are taking a transcriptome-wide approach to identifying and validating common genes that affect genetic risk in both breast and ovarian cancers.
DCell, a visible neural network, uses deep learning techniques to model cellular behavior almost as accurately as has been observed in laboratory settings.
The document is one of the early fruits of GA4GH Connect, a five-year initiative to better align the group's objectives with the key needs of the international genomic data community.
The LOHGIC algorithm is currently being used to analyze tumor sequencing assay results as part of the Rutgers Cancer Institute's precision medicine program.
Among other projects, the company will make improvements to its internal bioinformatics pipeline and develop a 5,000-sample cohort for oncology research use.
The partners will integrate genomic, imaging, and other data to identify new therapies and personalize treatments for patients with neurological and neurodegenerative diseases.
A Baylor study compared 25 algorithms in terms of their ability to characterize missense variants and found significant disagreement in their predictions.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
